Bajaj Finance reported robust performance in Q1FY25 with healthy momentum in AUM driven by revival in customer accretion Bajaj Finance reported robust performance in Q1FY25 with healthy momentum in AUM driven by revival in customer accretion

Posted on by Raj Gaurav Rai

Bajaj Finance reported robust performance in Q1FY25 with healthy momentum in AUM driven by revival in customer accretion Bajaj Finance reported robust performance in Q1FY25 with healthy momentum in AUM driven by revival in customer accretion

Please follow and like us:

Related posts:

No related posts.

Related Posts

Rail Vikas Nigam’s joint venture with Kerala Rail Development Corp wins an order worth Rs 156.5 crore from the Southern Railway to provide automatic signalling on the Ernakulam-Vallattol Nagar section of Thiruvananthapuram division. Reliance Industries’ telecom arm Jio expands its 1,800 MHz band by acquiring 5 MHz paired spectrum in Bihar for Rs 420.2 crore and 9.4 MHz paired spectrum in West Bengal for Rs 553.4 crore. It secures the spectrum for 20 years Rail Vikas Nigam’s joint venture with Kerala Rail Development Corp wins an order worth Rs 156.5 crore from the Southern Railway to provide automatic signalling on the Ernakulam-Vallattol Nagar section of Thiruvananthapuram division. Reliance Industries’ telecom arm Jio expands its 1,800 MHz band by acquiring 5 MHz paired spectrum in Bihar for Rs 420.2 crore and 9.4 MHz paired spectrum in West Bengal for Rs 553.4 crore. It secures the spectrum for 20 years

Rail Vikas Nigam's joint venture with Kerala Rail Development Corp wins an order worth Rs 156.5 crore from the Southern Railway to provide automatic signalling […]

Dr. Reddys -USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. -Sales of the product for the past 12 months ended March 2024 were $51.8 million Dr. Reddys -USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. -Sales of the product for the past 12 months ended March 2024 were $51.8 million

Dr. Reddys -USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. -Sales of […]